Innovation and management are key differentiators in today's diverse pharmaceutical industry. Investment analyst and former physician Craig Gordon discusses what he looks for in a focused portfolio of pharma and biotech companies.
Our chart shows that U.S. valuations are not as high as they seem when removing the largest tech stocks, and are comparable to overseas markets.
Emerging markets are benefiting from the global economic recovery, but does the current rally have staying power? A portfolio manager of Capital Group Emerging Markets Total OpportunitiesSM Fund (Canada) weighs in.
Shaw Wagener, a portfolio manager of Capital Group Emerging Markets Total OpportunitiesSM Fund (Canada), shares his thoughts from a recent trip to IT hotbed Shenzhen.
An on-the-ground look at what's happening in Asia and the opportunities for investors around the world.